Towards an Optimal Decision Threshold for Specific I g E to r C an s 3 the Non‐Specific Lipid Transfer Protein of Cannabis sativa
- 29 July 2025
- journal article
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 56 (3) , 243-251
Abstract
Background: Cannabis allergy is increasingly reported, with Can s 3 as a major allergen. Investigations into sensitisation to Can s 3 utilise sophisticated techniques, including the cytometric bead assay and the basophil activation test. This study aims to utilise a fluorescence enzyme immunoassay to quantify sIgE to Can s 3, employing a recombinant Can s 3 protein. Methods: This study included 104 cannabis allergic patients, 20 healthy controls and 70 exposed atopic controls. Specific IgE by a fluorescence enzyme immunoassay or cytometric bead assay and the basophil activation test all used the same recombinant allergen. Two‐graph ROC curves were used to determine the clinically validated allergen‐specific cut‐off for maximal sensitivity and specificity and to facilitate direct comparison of the test performances. Results: Twenty‐two individuals were non‐responding in the basophil activation test and were excluded from all analyses involving basophil activation test results. The clinically validated cut‐off points are > 0.16 kU A /L, ≥ 0.14 kU A /L and > 5% for a fluorescence enzyme immunoassay, cytometric bead assay and basophil activation test, respectively. Utilising these thresholds, the fluorescence enzyme immunoassay exhibited a sensitivity of 72% and specificity of 74%, the cytometric bead assay demonstrated a sensitivity of 49% and specificity of 89%. In responders, the basophil activation test exhibited a sensitivity of 51% and specificity of 82%. Remarkably, low positive fluorescence enzyme immunoassay results, particularly below 0.35 kU A /L, are negative for both cytometric bead assay and basophil activation test. Conversely, utilising the conventional threshold of > 0.35 kU A /L, the sIgE a fluorescence enzyme immunoassay results exhibited greater congruence with those of the cytometric bead assay and basophil activation test. Conclusion: This study underscores the complexity of establishing an optimal decision threshold for the sIgE rCan s 3 fluorescence enzyme immunoassay and indicates that the clinically validated decision cut‐off may not always represent the most efficacious approach.Keywords
This publication has 20 references indexed in Scilit:
- Bronchial Challenge in the Diagnosis of Cannabis AllergyCurrent Allergy and Asthma Reports, 2024
- IgE-Mediated Cannabis Allergy and Cross-Reactivity Syndromes: A Roadmap for Correct Diagnosis and ManagementCurrent Allergy and Asthma Reports, 2024
- A review of cannabis allergy in the early days of legalizationAnnals of Allergy, Asthma & Immunology, 2022
- Establishing diagnostic strategies for cannabis allergyExpert Review of Clinical Immunology, 2022
- In search of the golden ratio for cannabis allergy: Utility of specific allergen‐to‐total IgE ratiosAllergy, 2021
- The diagnosis of non-life-threatening immediate penicillin allergy should not rest upon low sIgE results between 0.10 kUA/L and 0.35 kUA/L in isolationClinica Chimica Acta, 2020
- Cannabis allergy: A diagnostic challengeAllergy, 2018
- IgE-reactivity profiles to nonspecific lipid transfer proteins in a northwestern European countryJournal of Allergy and Clinical Immunology, 2017
- IgE-binding properties of a recombinant lipid transfer protein from Cannabis sativaAnnals of Allergy, Asthma & Immunology, 2014
- Sensitization to Cannabis sativa caused by a novel allergenic lipid transfer protein, Can s 3Journal of Allergy and Clinical Immunology, 2007